Pharmafile Logo

Q3 results

- PMLiVE

Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shows promise in fatty liver disease MASH

Metabolic dysfunction-associated steatohepatitis is the second most common contributor to liver transplantation in the US

- PMLiVE

Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

The company is seeking approval of donanemab to treat patients with early stages of the disease

- PMLiVE

Moderna shares positive late-stage results for COVID-19/flu combination vaccine

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

FDA approves Geron’s Rytelo to treat lower-risk myelodysplastic syndrome patients

The oligonucleotide telomerase inhibitor is administered as an intravenous infusion every four weeks

- PMLiVE

AstraZeneca’s Tagrisso combination receives CHMP recommendation for advanced lung cancer

More than 450,000 people are diagnosed with lung cancer every year in Europe

- PMLiVE

Eli Lilly gains rights to QurAlis’ neurodegenerative disease therapy in deal worth over $620m

The agreement gives the company global rights to QRL-204 and other UNC13A-targeting compounds

- PMLiVE

WHA announces progress of WHO Member States to conclude pandemic agreement

The agreement is aimed at preventing a repeat of the global health, economic and social impacts of the COVID-19 pandemic

- PMLiVE

Pfizer’s one-time haemophilia B therapy Durveqtix receives CHMP recommendation

More than 38,000 people worldwide are currently affected by the inherited bleeding disorder

- PMLiVE

Eli Lilly commits further $6.5m to UNICEF for young people at risk of noncommunicable diseases

The new funding builds on the company’s initial commitment of $14.4m in 2022

- PMLiVE

Bristol Myers Squibb’s Breyanzi receives FDA approval for mantle cell lymphoma

The rare form of non-Hodgkin lymphoma accounts for around 3% of all NHL cases

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval for use in older adults

The approval marks the first time an mRNA vaccine has been approved for a disease other than COVID-19

- PMLiVE

Eli Lilly to invest additional $5.3bn totalling $9bn in US manufacturing sites

The investment will provide an additional 200 jobs and more than 5,000 construction jobs during development of the site

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links